Executive Employment AgreementExecutive Employment Agreement • May 17th, 2016 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURESupplemental Indenture • May 17th, 2016 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations • New York
Supplemental Indenture (this “Supplemental Indenture”), dated as of April 4, 2016, among DenTek Holdings, Inc., a Delaware corporation, DenTek Oral Care, Inc., a Tennessee corporation (each, a “Guaranteeing Subsidiary”), each a subsidiary of Prestige Brands, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank National Association, a national banking association, as trustee (the “Trustee”).
Amendment No. 2 to TRANSITIONAL MANUFACTURING AND SUPPLY AGREEMENTTransitional Manufacturing and Supply Agreement • May 17th, 2016 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations
WHEREAS, Supplier and Prestige entered into a Transitional Manufacturing and Supply Agreement dated January 31, 2012, as amended by Amendment Number One to the Transitional Manufacturing and Supply Agreement dated as of June 25, 2013 (collectively, the “Agreement”), whereby Supplier agreed to supply and Prestige agreed to purchase certain products (“Products”); and
AMENDMENT NUMBER ONE TO THEManufacturing and Supply Agreement • May 17th, 2016 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER ONE to the Transitional Manufacturing and Supply Agreement (the "Amendment") is made and entered into as of the 25th day of June, 2013, by and between GlaxoSmithKline Consume1· Healthcare L.P., a Delaware limited liability company ("GSK"), and Medtech Products Inc., a Delaware corporation ("Buyer").
